December 2016
-
GlaxoSmithKline and Theravance have submitted an application for the Anoro Ellipta umeclidinium bromide /vilanterol (UMEC/VI) DPI for the treatment of COPD to the Japanese Ministry of Health, Labour and Welfare (MHLW), the companies said. The… Read more . . .
-
GW Pharmaceuticals has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance in response to its patent application for a metered dose spray device for sublingual delivery of… Read more . . .
-
Powder characterization specialist Freeman Technology has hired Doug Millington-Smith as Applications Specialist at the company’s UK headquarters. As Applications Specialist, he will support users of the company’s FT4 Powder Rheometer, which is used for characterization… Read more . . .
-
Galapagos subsidiary Argenta has signed an agreement with Boehringer Ingelheim to provide respiratory drug discovery services for “an undisclosed target within Boehringer Ingelheim’s respiratory disease portfolio,” the company said. On its website, Argenta says that… Read more . . .
-
In a Phase 2 study of Civitas Therapeutics’ CVT-301 inhaled levodopa (L-dopa), Parkinson’s disease patients with motor fluctuations (OFF episodes) who used the drug experienced “rapid and durable” motor function improvement, the company announced. The… Read more . . .
-
According to Impel NeuroPharma, the results of a human proof of concept study using SPECT imaging demonstrated nose-to-brain delivery by its Precision Olfactory Delivery (POD) device. The company said that the SPECT images showed deposition… Read more . . .
-
Besins Healthcare will license the Muco (μco) intranasal system from Shin Nippon Biomedical Laboratories (SNBL) for delivery of its BHR-310 progesterone powder, which it is developing for the treatment of mild traumatic brain injury (TBI).… Read more . . .
-
The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted to recommend approval of of GSK and Theravance’s Breo Ellipta fluticasone furoate/vilanterol (FF/VI) DPI for the treatment of COPD. The PADAC meeting had been rescheduled from… Read more . . .
-
Savara Pharmaceuticals has announced the commencement of a Phase 2 clinical trial of its AeroVanc inhaled dry powder vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. The randomized,… Read more . . .
-
According to Celsus Therapeutics, it has received patents for several of its pipeline drugs, including MRX-4, and intranasal multifunctional anti-inflammatory drug for the treatment of allergic rhinitis. Celsus changed its name from Morria Biopharmaceuticals in… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland